Levodopa/benserazide

Levodopa/benserazide
Combination of
Levodopa	Dopamine agonist
Benserazide	Decarboxylase inhibitors
Clinical data
Trade names	Prolopa, Madopar, others
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
ATC code	N04BA02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); In general: ℞ (Prescription only);
Identifiers
KEGG	D02135;

Levodopa/benserazide, sold under the brand name Prolopa among others, is a fixed-dose combination medication used for the treatment of Parkinson's disease.^[2]^[3]^[4]

Medical uses

Levodopa/benserazide is indicated for the treatment of Parkinson's disease with the exception of drug-induced parkinsonism.^[2]^[3]^[4]

References

^ "Levodopa".
^ ^a ^b ^c ^d "Madopar Product Information". Medsinfo. 8 July 2019. Retrieved 2 September 2024.
^ ^a ^b ^c "Prolopa Product information". Health Canada. 25 April 2012. Retrieved 8 January 2023.
^ ^a ^b ^c "Madopar 100 mg/25 mg Dispersible Tablets - Summary of Product Characteristics (SmPC)". (emc). 8 April 2020. Retrieved 9 January 2023.

External links

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] "Levodopa".

[Madopar_PI-2] "Madopar Product Information". Medsinfo. 8 July 2019. Retrieved 2 September 2024.

[Prolopa_PI-3] "Prolopa Product information". Health Canada. 25 April 2012. Retrieved 8 January 2023.

[Madopar_SmPC-4] "Madopar 100 mg/25 mg Dispersible Tablets - Summary of Product Characteristics (SmPC)". (emc). 8 April 2020. Retrieved 9 January 2023.

[1]

[2]

[3]

[4]